Understanding the various aspects of clinical trials can be overwhelming, and many patients with myeloproliferative neoplasms (MPNs) may be hesitant to join because of common misconceptions. However, ...
~ Late-breaking Phase 2 trial data evaluating the safety and efficacy of 25 mg of lorundrostat in participants with hypertension and comorbid CKD to be presented~ ~ Phase 3 data of the Launch-HTN ...
BRANFORD, Conn., May 28, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today ...
SUNNYVALE, Calif., Jan. 27, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [NASDAQ: BCDA] today announced that the results of its double-blind randomized placebo-controlled CardiAMP HF Phase 3 study have ...
Patients with cancer often miss out on the benefits of clinical research either due to a dearth of communication from doctors or a lack of comprehension of their complex nature, according to a speaker ...
STATEN ISLAND, N.Y., April 25, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of ...
PARIS, France – October 05, 2025 – 5:00 PM CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on ...
Meet Your ETF AI Analyst Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals ...
TEL AVIV, Israel and WALTHAM, Mass., Nov. 5, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology ...
Exact presentation times may be subject to change. About Ocular Therapeutix, Inc. Ocular Therapeutix, Inc. is a fully-integrated biopharmaceutical company committed to redefining the retina experience ...
Identifying GP2 specific T cell immune response at baseline prior to treatment with GP2 has potential to predict breast cancer recurrence risk and timing of recurrence A positive baseline immune ...
TipRanks on MSN
Cynata Therapeutics Unveils Updated Investor Presentation
Cynata Therapeutics Limited ( ($AU:CYP) ) has shared an update. Cynata Therapeutics Limited has released an updated investor presentation, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback